Effects of Fenofibric Acid on Carotid Intima-Media Thickness in Patients With Mixed Dyslipidemia on Atorvastatin Therapy: Randomized, Placebo-Controlled Study (FIRST).
CONCLUSIONS: Compared with atorvastatin monotherapy, FA plus atorvastatin did not further decrease cIMT progression in high-risk patients with mixed dyslipidemia.
PMID: 24743431 [PubMed - as supplied by publisher] (Source: Arteriosclerosis, Thrombosis and Vascular Biology)
Source: Arteriosclerosis, Thrombosis and Vascular Biology - April 17, 2014 Category: Cardiology Authors: Davidson MH, Rosenson RS, Maki KC, Nicholls SJ, Ballantyne CM, Mazzone T, Carlson DM, Williams LA, Kelly MT, Camp HS, Lele A, Stolzenbach JC Tags: Arterioscler Thromb Vasc Biol Source Type: research
Effect of ABT-335 (fenofibric acid) on meal-induced oxidative stress in patients with metabolic syndrome
Abstract: Objective: Examine the effect of ABT-335 (fenofibric acid) on postprandial lipemia and susceptibility of plasma lipoproteins to Cu++-mediated oxidation in patients with metabolic syndrome.Methods and results: This is a randomized double-blind, placebo-controlled study with cross-over and includes a 4-week wash-out period between the two treatment periods. At the end of each 8-week treatment period, subjects were challenged with a standardized mixed meal followed by blood collection over the ensuing 6 h. Plasma lipoproteins were isolated by a combination of ultracentrifugation and FPLC for the continuous monitori...
Source: Atherosclerosis - November 25, 2013 Category: Cardiology Authors: Ngoc-Anh Le, Monica Farkas-Epperson, Mary Ellen Sweeney, Peter W.F. Wilson, W. Virgil Brown Tags: Clinical & Population Research - Epidemiology, Biomarkers, Nutrition Source Type: research
Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
This study aimed at investigating the effect of particle size of LMP on drug release in vitro as well as absorption in vivo in order to get a better understanding on the effect of degradation of lipid particles on drug solubilisation and absorption. Fenofibrate, a model poorly water-soluble drug, was incorporated into LMP in this study using probe ultrasound sonication. The resultant LMP were characterised in terms of particle size, size distribution, zeta potential, entrapment efficiency, in vitro lipolysis and in vivo absorption in rat model. LMP of three different particle sizes i.e. approximately 100nm, 400nm, and 10μ...
Source: European Journal of Pharmaceutical Sciences - October 14, 2013 Category: Drugs & Pharmacology Authors: Borkar N, Xia D, Holm R, Gan Y, Müllertz A, Yang M, Mu H Tags: Eur J Pharm Sci Source Type: research
A Randomized, Double-Blind Study of Fenofibric Acid Plus Rosuvastatin Compared With Rosuvastatin Alone in Stage 3 Chronic Kidney Disease.
CONCLUSIONS: The data suggest that, after 16 weeks of therapy, FA + R has an acceptable safety profile and improved TG and HDL-C efficacy versus R. FA + R combination therapy may thus further improve lipid parameters in patients with stage 3 CKD and mixed dyslipidemia. ClinicalTrials.gov identifier: NCT00680017.
PMID: 23891363 [PubMed - as supplied by publisher] (Source: Clinical Therapeutics)
Source: Clinical Therapeutics - July 25, 2013 Category: Drugs & Pharmacology Authors: Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC Tags: Clin Ther Source Type: research
Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway.
Abstract
Fenofibrate and ciglitazone belong to the classes of fibrates and thiazolidinediones, respectively. Their pharmacological actions on peroxisome proliferator-activated receptors (PPARs) present a potential therapy for hyperlipidemia and hyperglycemia. However, the melanogenesis affected by PPAR ligands in melanocytes has not been well investigated. By determining the melanin content of cells treated with PPAR agonists, we showed that fenofibrate significantly reduced melanin synthesis, but its major active metabolite, fenofibric acid, did not. Notably, the suppression of melanogenesis by fenofibrat...
Source: Chemico-Biological Interactions - July 18, 2013 Category: Molecular Biology Authors: Huang YC, Liu KC, Chiou YL, Yang CH, Chen TH, Li TT, Liu LL Tags: Chem Biol Interact Source Type: research
Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy [Patient-Oriented and Epidemiological Research]
We examined the effect of rare genetic variants in the APOA5 gene region on plasma HDL-C, apolipoprotein A-I (apoA-I), and TG response to fenofibric acid monotherapy and in combination with statins. The APOA5 gene region was sequenced in 1,612 individuals with mixed dyslipidemia in a randomized trial of fenofibric acid alone and in combination with statins. Student's t-test and rare variant burden tests were used to examine plasma HDL-C, apoA-I, and TG response. Rare APOA5 promoter region variants were associated with decreased HDL-C and apoA-I levels in response to fenofibric acid therapy; rare missense variants were asso...
Source: The Journal of Lipid Research - June 11, 2013 Category: Lipidology Authors: Brautbar, A., Barbalic, M., Chen, F., Belmont, J., Virani, S. S., Scherer, S., Hegele, R. A., Ballantyne, C. M. Tags: Patient-Oriented and Epidemiological Research Source Type: research
